Delisting risk
PDS Biotechnology
Develops investigational immunotherapies for cancer and infectious diseases.
$0.2136
After-hours close+0.00 (+2.05%)
At close$0.2093(−3.95%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 9.03%5.05M sharesInsiders 0.25%140.1K sharesOther 90.72%50.73M shares
Shares outstanding 55.92M · Float 54.40M · 97.3% free float
Institutions13F, as of Mar 31, 2026
42 holders · 5.05M shares · 9 new positions · 19 increased · 9 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.63M | 2.92% | +1.63Mnew | May 15, 2026 |
| Geode Capital Management, LLC | 660.2K | 1.18% | +139.8K | May 15, 2026 |
| BlackRock, Inc. | 554.0K | 0.99% | +31.8K | May 13, 2026 |
| Vanguard Fiduciary Trust Co | 307.3K | 0.55% | +307.3Knew | May 8, 2026 |
| Blair William & Co/IL | 300.0K | 0.54% | +50.0K | May 8, 2026 |
| Renaissance Technologies LLC | 220.8K | 0.39% | +44.1K | May 14, 2026 |
| Inspirion Wealth Advisors, LLC | 182.0K | 0.33% | +1.5K | Apr 8, 2026 |
| Armistice Capital, LLC | 173.6K | 0.31% | −2.66M | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Stephen C. Glover | director | 78.9K | 0.14% | Mar 3, 2025 |
| Gregory Gene Freitag | director | 61.2K | 0.11% | Mar 3, 2025 |
7 ten-percent owners hold 820.0K shares by Form 4, outside the officers-and-directors figure above · 15 people have not refiled in the last 18 months (2.58M shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.